Total Funding
41
Total FundingSeries E raised
Growth Score
pts
Heat Score
-17 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
4043599
NitroMed is an emerging pharmaceutical company with substantial expertise and intellectual property in nitric oxide-based drug development.
Acquired by 
Deerfield Capital Management
- Joseph Loscalzo: Co-Founder and DirectorPast Role: Harvard Medical School, Head of Department of Medicine and Physician-in-Chief
About the Company
NitroMed is an emerging pharmaceutical company that discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the therapeutic benefits of the naturally-occurring molecule nitric oxide.
NitroMed is conducting a late-stage confirmatory trial of our lead nitric oxide-enhancing drug, BiDil, for the treatment of heart
failure in African Americans.
